Abstracts - faqs.org

Abstracts

Business, international

Search abstracts:
Abstracts » Business, international

Denmark: Novo's partner in diabetes drug to back out

Article Abstract:

Novartis, the Swiss pharmaceutical giant, has unexpectedly backed out of its diabetes drug co-operation deal with Danish Novo Nordisk. Novo Nordisk now stands alone with one of the company's most important blockbuster projects i.e. a new diabetes tablet that is expected to generate sales of more than US$1bn. The parties had signed a deal to market the substance NN622, a so-called double-acting insulin sensitizer for the treatment of type 2 diabetes. Novo Nordisk ceo Lars Rebien Sorensen says that company will go on with the project that is to enter the 3rd phase later this year. He expects Novo to find a new partner for the project within a year.

Publisher: A/S Forlaget Borsen
Publication Name: Boersen
Subject: Business, international
ISSN:
Year: 2001
Novartis AG

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


DENMARK: NOVO TO CO-OPERATE IN DIABETES RESEARCH

Article Abstract:

Novo Nordisk, the Danish pharmaceuticals company, is to establish a European research programme focusing on the treatment of diabetes. It wants to attract non-profit organizations in Europe for this research. Yesterday, Novo Nordisk signed a unique co-operation programme with two non-profit organizations regarding a new research programme, the European Diabetes Research Programme. The programme consists of two projects; one focusing on Juvenile Diabetes Foundations and the other on the so-called diabetes type 2.

Publisher: A/S Forlaget Borsen
Publication Name: Boersen
Subject: Business, international
ISSN:
Year: 2000

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


DENMARK: NOVO NORDISK SIGNS DEAL WITH LIFESCAN

Article Abstract:

Novo Nordisk, the Danish pharmaceutical company, has signed a global co-operation deal with LifeScan, the company owned by Johnson & Johnson, about the development and marketing of new systems of administering medicines to diabetics who require daily insulin injections. LifeScan has its headquarters in California.

Publisher: A/S Forlaget Borsen
Publication Name: Boersen
Subject: Business, international
ISSN:
Year: 2001
Johnson & Johnson

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Denmark, Novo Nordisk A/S, Diabetes research
Similar abstracts:
  • Abstracts: Denmark: Ico-Ica not successful in expansion strategy. DENMARK: 7-ELEVEN TO EXPAND IN DENMARK
  • Abstracts: Denmark: BHJ aims to boost profits. DENMARK:MEAT INDUSTRY & FOOD-AND-MOUTH DISEASE. DENMARK: NOWACO'S INTERIM RESULTS
  • Abstracts: DENMARK: EGMONT TO FOCUS MORE ON THE NEW MEDIA. DENMARK: EGMONT TO CLOSE DOWN EON.DK. DENMARK: NOVO BUYS 10% OF E-COMMERCE MARKETPLACE
  • Abstracts: DENMARK: NEW MARKET FOR SMS SERVICES IN JEOPARDY. Denmark: Tetra network to be delayed. DENMARK: DYREMOSE CRITICIZES 3G-LICENSE AUCTION
  • Abstracts: FRANCE: THE MARKET OF AIR FRESHENERS. France: Lever enriches its wipe range. FRANCE: REFRESH DE CAJOLINE FROM LEVER
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.